Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 152317
                    [Title] => Giant German pharma set to launch newest  anti-"ED" preparation
                    [Summary] => Leverkusen, Germany - First Pivotal Phase III data for vardenafil,  Bayer’s new,  highly selective phosphodiesterase-5 inhibitor for erectile dysfunction (ED),  show statistically significant improvements in erectile function and consistency in response among up to 85 percent of the broad population of men treated.  The data was presented last December at the Annual Meeting of the Sexual Medicine Society of North America (SMSNA) in Charleston,  South Carolina/USA.


                    [DatePublished] => 2002-03-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

FIRST PIVOTAL PHASE

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 152317
                    [Title] => Giant German pharma set to launch newest  anti-"ED" preparation
                    [Summary] => Leverkusen, Germany - First Pivotal Phase III data for vardenafil,  Bayer’s new,  highly selective phosphodiesterase-5 inhibitor for erectile dysfunction (ED),  show statistically significant improvements in erectile function and consistency in response among up to 85 percent of the broad population of men treated.  The data was presented last December at the Annual Meeting of the Sexual Medicine Society of North America (SMSNA) in Charleston,  South Carolina/USA.


                    [DatePublished] => 2002-03-01 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

        )

)

abtest

Giant German pharma set to launch newest anti-"ED" preparation

March 1, 2002 - 12:00am

Leverkusen, Germany - First Pivotal Phase III data for vardenafil, Bayer’s new, highly selective phosphodiesterase-5 inhibitor for erectile dysfunction (ED), show statistically significant improvements in...

Health And Family